Skip to main content
All lobbying filings

HARMONY BIOSCIENCES

HARMONY BIOSCIENCES filed a Q1 report for HARMONY BIOSCIENCES on April 14, 2026.

Lobbying for HARMONY BIOSCIENCES · pharmaceuticals

All filings by HARMONY BIOSCIENCES · Everything HARMONY BIOSCIENCES has reported

 Filing · LD-2 quarterly report Q1 report
Reporting period
1st Quarter 2026
Jan 1 - Mar 31 · Posted Apr 14, 2026
Expenses
$180,000
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
Pennsylvania

Official filing document

 Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 1

Cameron's Law (HR 1414) EPIC Act (HR 1492/S 832) HR 1672 Maintaining Investments in New Innovation Act Issues related to protecting patient access to medicines Issues related to protecting orphan drug policies Issues related to most-favored-nation policies

 Bills named in this filing 3
  • H.R. 1414
    Cameron’s Law
  • H.R. 1492
    To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
  • H.R. 1672
    Maintaining Investments in New Innovation Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem